BrunoCarneiro DeMedeirosMD

Hematology • Stanford, CA

Assistant Professor, Medicine - Hematology, Stanford University Medical Center

Join to view full profile

Are you Dr. Medeiros?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 53 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
300 Pasteur Dr
Stanford, CA 94305
Phone+1 650-723-4000

Fax+1 650-724-5203

Summary

Dr. Bruno Medeiros, MD is a hematologist in Stanford, California. He is currently licensed to practice medicine in California and Colorado. He is affiliated with Stanford Health Care and is an Assistant Professor at Stanford University Medical Center.

Education & Training

University of ColoradoFellowship, Hematology and Medical Oncology, 2002 - 2005
University of ColoradoResidency, Internal Medicine, 2000 - 2002
University of ConnecticutInternship, Internal Medicine, 1999 - 2000
Federal University of Parana Faculty of MedicineClass of 1998

Certifications & Licensure

CA State Medical License 2006 - 2026
CO State Medical License 2002 - 2005

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013

Clinical Trials

Phase 2 Study of Temozolomide to Treat Poor Risk / Refractory Acute Myeloid Leukemia Start of enrollment: 2007 Dec 01
Completed
Phase 2
Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML) Start of enrollment: 2005 Jul 01
Completed
Phase 1, Phase 2
Phase 1-2 of Azacitidine + Lenalidomide for Previously Untreated Elderly Patients With Acute Myeloid Leukemia (AML) Start of enrollment: 2009 Apr 01
Completed
Phase 1, Phase 2
Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML Start of enrollment: 2009 May 01
Completed
Phase 1, Phase 2
Phase II Study of VELCADE for Relapsed or Refractory T-cell Prolymphocytic Leukemia Start of enrollment: 2010 Jun 01
Withdrawn
Phase 2
Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML) Start of enrollment: 2010 Oct 01
Completed
Phase 1
Single Agent Lenalidomide in Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia Start of enrollment: 2011 Jan 01
Terminated
Phase 2
Azacitidine + Lenalidomide Combo in the Elderly With Previously Treated AML & High-Risk MDS Start of enrollment: 2011 Aug 01
Terminated
Phase 2
Temozolomide Plus Vorinostat in Relapse/Refractory Acute Myeloid Leukemia (AML) Start of enrollment: 2013 May 01
Completed
Phase 2
Analysis of Cutaneous and Hematologic Disorders by High-Throughput Nucleic Acid Sequencing Start of enrollment: 2011 Jun 01
Terminated
Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia Start of enrollment: 2012 Dec 13
Completed
Phase 3
Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia Start of enrollment: 2013 Feb 12
Completed
Phase 3
Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia Start of enrollment: 2013 May 07
Completed
Not Applicable
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Start of enrollment: 2013 May 01
Withdrawn
Phase 2
Decitabine and Midostaurin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2013 Jun 01
Terminated
Phase 2
Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Start of enrollment: 2014 Feb 01
Terminated
Phase 1
Safety and Efficacy Study of Pracinostat With Azacitadine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) Start of enrollment: 2013 Dec 24
Completed
Phase 2
Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients Start of enrollment: 2013 Jul 19
Completed
CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Start of enrollment: 2014 Feb 03
Completed
Phase 2
Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Start of enrollment: 2014 Mar 01
Terminated
Phase 2
MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Start of enrollment: 2014 Dec 01
Terminated
Phase 1
Ibrutinib, Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Start of enrollment: 2016 Nov 01
Terminated
Phase 1
Join now to see all

Publications & Presentations

PubMed

59 citations
Genomic landscape of neutrophilic leukemias of ambiguous diagnosis
Haijiao Zhang, Beth Wilmot, Daniel Bottomly, Kim Hien T. Dao, Emily A. Stevens
Blood. 2019-09-12
119 citations
Impact of NPM1/FLT3-ITD Genotypes Defined by the 2017 European LeukemiaNet in Patients With Acute Myeloid Leukemia
Konstanze Döhner, Christian Thiede, Nikolaus Jahn, Ekaterina Panina, Agnes Gambietz
Blood. 2020-01-30
18 citations
Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial.
Nikolaus Jahn, Ekaterina Jahn, Maral Saadati, Lars Bullinger, Richard A Larson
Leukemia. 2022-09-01

Press Mentions

Celator Pharmaceuticals® Announces Positive Results in Patients with FLT3 Mutation from the Phase 3 Trial in High-Risk Acute Myeloid LeukemiaJune 14th, 2016